AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease

Phase 2ACI-24Neutral

AI Analysis

Summary

AC Immune reports interim 12-month data from the Phase 1b/2 ABATE trial evaluating ACI-24 in prodromal Alzheimer's disease patients. No efficacy or safety details are provided in the headline.

Clinical Trial Data

Phase

1b/2

Outcome Details

Interim 12-month data from Phase 1b/2 ABATE trial

Importance:6/10

Sentiment:

0.00

Alzheimer's DiseaseClinical TrialPhase 1b/2Data Readout

Related Companies

$ACIU

Read the original article

Published by yahoo_finance on June 30, 2026 11:00 AM

Read Original